<div id="readability-page-1"><p>Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Evolus, retaining the price target of $13.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Douglas Tsao has given his Buy rating due to a combination of factors, including Evolus’ solid first-quarter performance and confirmation of its 2026 outlook. The company modestly exceeded Street revenue expectations, sustained positive adjusted EBITDA for a second straight quarter, and reiterated guidance for double-digit revenue growth with improving margins, signaling an increasingly scalable business model.</p> <p>Tsao also views Evolus’ commercial strategy as well suited to a value-focused consumer backdrop, as the company emphasizes perceived value through loyalty programs and partnerships rather than aggressive discounting. Stable U.S. toxin market share, high account penetration, and rising loyalty membership indicate resilient engagement, supporting confidence that Evolus can navigate macro pressures and achieve its growth and profitability targets, which underpins the unchanged $13 price target and Buy rating.</p> <p>In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $15.00 price target.</p></div>

EOLS

SBIO

LABU

IBBQ

<p>Analyst Douglas Tsao of H.C. Wainwright has maintained a Buy rating on Evolus, reaffirming a price target of $13.00. This decision is based on Evolus' strong first-quarter performance, positive adjusted EBITDA, and guidance for double-digit revenue growth. Tsao highlights the company's effective commercial strategy and stable market share, indicating resilience amid macro pressures. Mizuho Securities also reiterated a Buy rating with a $15.00 price target.</p>

Tip Ranks

Evolus

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Mizuho Financial Group, Inc.

Mizuho Financial

Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed